Form 4: RAPT Therapeutics Director Acquires Stock Options in Lieu of Cash Compensation

Director Wendye Robbins acquired stock options in RAPT Therapeutics in lieu of cash compensation for board service.

Summary

• On March 31, 2025, Wendye Robbins, a director of RAPT Therapeutics, acquired stock options to purchase 49,432 shares of common stock at an exercise price of $1.22.
• The options vest in four equal quarterly installments throughout 2025, contingent upon continued service as a director.
• These options were granted in lieu of $52,500 in annual cash retainers for board and committee service, according to the Issuer's Amended and Restated Non-Employee Director Compensation Policy.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects a standard compensation practice that aligns director interests with shareholders, but doesn't contain any groundbreaking news.

Positives

• The acquisition of stock options by a director aligns their interests with those of the shareholders.
• Using stock options in lieu of cash preserves cash for the company.

Future Outlook

NA

Industry Context

Granting stock options to directors is a common practice to align their interests with shareholders and conserve cash, particularly for companies in the biotechnology sector.

Comparison to Industry Standards

• Many biotech companies use equity compensation for board members.
• Comparable companies like BioNTech and Moderna also utilize stock options as part of their director compensation packages.
• The vesting schedule of quarterly installments is fairly standard.

Stakeholder Impact

• Shareholders may view this as a positive sign that the director's interests are aligned with theirs.
• Employees may see this as a sign of the company's commitment to its leadership.

Key Dates

Keywords

RAPT Therapeutics, stock options, director compensation, Form 4, Wendye Robbins, insider transaction, equity compensation